Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Portal   Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA


Teresa GONZALEZ

Teresa González Martínez, PhD
Molecular and Celular diagnosis Unit of Cancer,lab 12.
IBSAL, IBMCC-Cancer research centre (USAL-CSIC)
Campus Miguel de Unamuno
Molecular Cytogenetics Lab, Dept. of Hematology
Salamanca University Hospital (HUSA)
37007 Salamanca (Spain)
teresa.gonzalez@mundo-r.com; teresa.gonzalez@mundo-r.com

EDUCATION AND WORK EXPERIENCE
2017-present Postdoctoral Researcher, Cancer Research Centre, University of Salamanca.
2005-2017 Staff Doctor and Coordinator of the oncohematological cytogenetics section in the Galician Public Foundation of Genomic Medicine (Santiago de Compostela).
2003-2005 PhD Researcher, Dept. of Physiology, School of Medicine (Santiago de Compostela).
2002 Post Graduate of Molecular Biology (University of Santiago de Compostela).
1994 University Degree in Biological Sciences (University of Santiago de Compostela).

MAIN TECHNICAL SKILLS AND COMPETENCES
She completed his thesis studying regulation of the cell cycle by kinase inhibitors in cells derived from transgenic mice without RB in the University of Santiago de Compostela (Galicia-Spain). For fifteen years she was coordinator of the oncohematological cytogenetics section in the Galician Public Foundation of Genomic Medicine, reference center in Galicia (Spain). In 2017, she joined the Molecular Cytogenetics group on Oncohematology at the CIC-Salamanca / Instituto de Biomedicina de Salamanca (IBSAL). Since then, she works between at the CIC and the Salamanca University Hospital (HUSA) in prognostic value of several cytogenetic abnormalities in NMPc, MDS, ALL, AML and CLL/CLS in haematological neoplasms diagnosis and the implementation of next generation sequencing to the clinical setting.

PUBLICATIONS
"Monosomal karyotype in chronic lymphocytic leukemia: association with clinical and biological features and potential prognostic significance". American Journal of Hematology. 2017. Maria Joao Baptista et al.
“Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions”. Oncotarget. 2017. Anna Puiggros et al.
“Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia”. Leukemia and lymphoma. 2017. González-Gascón Isabel et al.
“Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference”. Haematologica. 2016. Panagiotis Baliakas et al.
“Fluorescence in situ hybridization (FISH) of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic síndromes”. Leuk Lymphoma. 2015. Sánchez Castro M. et al. “The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic síndromes”. Blood Cancer J. 2015. K L McGraw et al.
"A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia". Hematol Oncol. 2015. González-Gascón I et al.
“A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia”. Plos One. 2015. Jesús M Hernández-Rivas. et al
“Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome”. Genes Chromosomes Cancer. 2014. Puiggros A et al.
“Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia”. Leuk Lymphoma. 2015. Sílvia Saumell et al.
“Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations”. British Journal of Haematology. 2013. Mallo M et al.
“Application of fish 7q in mds patients without monosomy 7 or 7q deletion by conventional g-banding cytogenetics: does –7/7q–detection by fish have prognostic value?”. Leukemia Research. 2013. Vera Ademà et al.
“Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion”. British Journal of Haematology. 2013. Anna Puiggros et al.
“Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma”. Genes Chromosomes Cancer, 2010. Espinet B et al.
“The mitochondrial genome is a "genetic sanctuary" during the oncogenic process”. PloS ONE. 2011. Seoane M et al.
“Study of the relation between the time course of the jak2v617f allele burden and the clinical evolution in patients with myeloproliferative neoplasms; a single center study”. Acta Haematologica Polonica. 2009. Sobas MA et al.
“Retinoblastoma loss modulates DNA damage response favoring tumor progression”. PLoS ONE. 2008. Seoane M et al.
“Inhibition of Cdk4 activity enhances translation of p27kip1 in quiescent Rb-negative cells”. The Journal of Biological Chemistry. 2003. Teresa González et al.


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case reports   Journals   Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA